Philips and MIT IMES develop enhanced critical care data set to give researchers and educators access to advance clinical understanding and AI in healthcare
18 Abril 2023 - 11:00AM
April 18, 2023
Latest clinical data set of 200,000 patients from over 200
hospitals, includes pandemic data for a broader and dependable
foundation for machine learning
Amsterdam, the Netherlands and Cambridge, MA, USA
– Royal Philips (NYSE: PHG, AEX: PHIA), a health
technology provider, today announced an expansion of its initiative
with the Institute for Medical Engineering and Science (IMES) at
the Massachusetts Institute of Technology (MIT) to allow health
care researchers access to a new critical care data set to help
advance machine learning and artificial intelligence (AI) in
healthcare. The updated eICU Collaborative Research Database
(eICU-CRD) includes de-identified data of 200,000 critical care
patients, including patients who were impacted by COVID-19. The
broader and clinically dependable data set will support the
development of solutions that improve patient care and clinical
outcomes.
During the COVID-19 pandemic, eICU and critical care saw a
dramatic increase of patients and unique challenges in the way that
care was provided, prompting Philips and IMES to expand the
original data set, first released in 2016. The new secure database
includes de-identified and detailed clinical information such as
vital signs, pharmacy and medication orders, laboratory results,
diagnoses, and novel severity of illness scores. The dataset gives
comprehensive insights on patient treatments, co-morbidities,
readmissions, and clinical outcomes.
Researchers at Philips and the Laboratory of Computational
Physiology within IMES will grant researchers around the world
access to the data to help develop advanced algorithms and provide
new insights on critical care. The Laboratory of Computational
Physiology will continue to serve as the academic research hub for
the initiative and will provide and maintain access, as well as
help educate researchers on the database and offer a platform for
collaboration. The database is available for medical research, to
those who are credentialed, who take human subjects training, and
who agree to a data use agreement.
“The database, which includes patient information from 2020 and
2021, now contains significant overlap with the Covid-19 pandemic,
yielding valuable patient data for research,” said Leo Anthony
Celi, principal research scientist and clinical research director
at the Laboratory of Computational Physiology at IMES. “This
updated database is a vital resource for education, including in
many courses at institutions like Harvard, MIT and Stanford; and
training, as well as low-resource institutions,” said Jesse D.
Raffa, research scientist in the Lab for Computational Physiology
at IMES.
The eICU-CRD is the only dataset containing detailed critical
care data from over 200 hospitals across the U.S., representing
many ‘real-world’ challenges for successful deployment of
algorithms and models, which are often not readily apparent in
single-center datasets. Unlike other organizations that do not
share data or only share single source data sets, Philips shares
its data with credentialled researchers to help advance AI for
improving outcomes in human health. More than 3,000 users have used
the original database with citations in over 660 published academic
research papers, including in Nature, The New England Journal of
Medicine and the Journal of the American Medical Association.
“This initiative demonstrates our commitment to advancing
machine learning and AI efforts, by making eICU data available for
global research initiatives,” said Shiv Gopalkrishnan, General
Manager of EMR & Care Management at Philips. “This is how we
can enhance patient care and improve clinical outcomes: liberating
and connecting data across systems and applications with integrated
devices, systems and informatics, which can inform research with
patient insights that can help clinicians make the right decision
at the right time for their patients.”
For further information, please contact:Silvie
CasanovaPhilips North AmericaTel.+1 781 879 0692E-mail:
silvie.casanova@philips.com
Anna HogrebePhilips Global Press OfficeTel.: +1 416 270
6757E-mail: anna.hogrebe@philips.comMindy BlodgettMIT IMESTel.+1
617 324 4019E-mail: mblodget@mit.eduAbout Royal
PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading
health technology company focused on improving people's health and
well-being through meaningful innovation. Philips’ patient- and
people-centric innovation leverages advanced technology and deep
clinical and consumer insights to deliver personal health solutions
for consumers and professional health solutions for healthcare
providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, ultrasound, image-guided therapy, monitoring
and enterprise informatics, as well as in personal health. Philips
generated 2022 sales of EUR 17.8 billion and employs approximately
77,000 employees with sales and services in more than 100
countries. News about Philips can be found at
www.philips.com/newscenter.
About IMESThe Institute for Medical Engineering
and Science (IMES) at the Massachusetts Institute of Technology
(MIT) is an inclusive community of students, administrative staff,
research staff, and faculty who research, work, educate, and learn,
at the convergence of engineering, science, and medicine to
transform human health for all. More about IMES can be found at
imes.mit.edu.
- A researcher reviews patient data
Koninklijke Philips NV (NYSE:PHG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Koninklijke Philips NV (NYSE:PHG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024